戻る Agenda
Asia-2a : Beyond E17 - Holistic Implementation of E5 and E17 to Lead Global Drug Development from Asia
Session Chair(s)
Masafumi Yokota, DVM, PhD
Senior Director , Daiichi Sankyo Co., Ltd., Japan
Speaker(s)
Shuji Kamada
Reviewer, Office of New Drug V, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Yan Hou
Department of Biostatistics, School of Public Health, Peking University, China
Hye Jong Yoo, RPh
Executive Director, AstraZeneca , Korea, Republic of
William Wang, PhD
Executive Director, Merck & Co, Inc, United States
Janet Lv, MS, RPh
CEO, Shanghai Zhiqiaohang Medical Consulting Co., China